Algiax Announces Positive Data from Phase 2a Proof of Concept Study Evaluating AP-325 in Patients with Neuropathic Pain

Düsseldorf, GERMANY – February 04, 2025 – Algiax Pharmaceuticals, a clinical-stage biotech company focused on developing innovative treatments for chronic neuropathic pain, today announced compelling topline data from its Phase 2a clinical trial evaluating AP-325 for the treatment of neuropathic pain. The study demonstrated that the company’s lead candidate has the potential to rapidly reduce neuropathic pain as well as achieve long-lasting benefits for patients post treatment. AP-325 is a non-opioid small molecule aimed at reducing neuropathic pain by activating GABAA signalling. Neuropathic pain is a chronic condition that is oftentimes associated with an imbalance in excitatory and inhibitory neuronal signals. By consistently counteracting the excessive activation of neurons, AP-325 has the potential to revolutionize neuropathic pain management. “These results mark a significant step towards our vision of disarming chronic neuropathic pain and offering a well-tolerated treatment option without the risk of dependence to patients suffering from this debilitating condition “, commented Dr. Ingo Lehrke, CEO of Algiax Pharmaceuticals. “Based on these highly encouraging results, we are exploring the best path forward to rapidly deliver the benefits of AP-325 to patients suffering from chronic pain worldwide and improve their quality of life.” Key findings from the Phase 2a study with AP-325 include: Dr. Guido Koopmans, CSO of Algiax Pharmaceuticals, added, “With a lack of non-opioid treatment options for chronic neuropathic pain, there is a remaining high need for millions of patients worldwide. The clinical meaningful effects in our Phase 2a study, combined with the clean safety profile, in particular regarding central nervous system side effects seen with standard of care, underline AP-325’s unique potential to provide a paradigm shift in neuropathic pain management for patients.” The Phase 2a randomized, double-blinded, placebo-controlled trial evaluated the safety and efficacy of AP-325 as a monotherapy in patients with peripheral post-surgical neuropathic pain. The study enrolled 99 participants in Germany, Spain, the Czech Republic, Belgium, and France at a total of 27 sites.

The release as fetched from its publisher. algiax.com ↗